- Previous Close
113.92 - Open
113.78 - Bid 114.46 x 900
- Ask 114.54 x 800
- Day's Range
112.87 - 114.72 - 52 Week Range
99.14 - 134.63 - Volume
4,516,341 - Avg. Volume
9,475,667 - Market Cap (intraday)
290.362B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
21.21 - EPS (TTM)
5.40 - Earnings Date Oct 31, 2024
- Forward Dividend & Yield 3.08 (2.69%)
- Ex-Dividend Date Sep 16, 2024
- 1y Target Est
140.43
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
www.merck.com70,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MRK
View More
Performance Overview: MRK
Trailing total returns as of 8/9/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRK
View MoreValuation Measures
Market Cap
290.36B
Enterprise Value
316.80B
Trailing P/E
21.21
Forward P/E
14.18
PEG Ratio (5yr expected)
0.10
Price/Sales (ttm)
4.67
Price/Book (mrq)
6.66
Enterprise Value/Revenue
5.07
Enterprise Value/EBITDA
15.39
Financial Highlights
Profitability and Income Statement
Profit Margin
21.99%
Return on Assets (ttm)
11.38%
Return on Equity (ttm)
33.38%
Revenue (ttm)
62.48B
Net Income Avi to Common (ttm)
13.74B
Diluted EPS (ttm)
5.40
Balance Sheet and Cash Flow
Total Cash (mrq)
11.35B
Total Debt/Equity (mrq)
86.57%
Levered Free Cash Flow (ttm)
11.79B
Research Analysis: MRK
View MoreCompany Insights: MRK
MRK does not have Company Insights
Research Reports: MRK
View MoreDiscounted price offers buying opportunity
Merck is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an Animal Health division. MRK shares are included in the S&P 500.
RatingPrice TargetU.S. stocks sold off across the board in Thursday following soft economic data.
U.S. stocks sold off across the board in Thursday following soft economic data. The ISM manufacturing data hit an 8-month low. The weekly jobless claims rose more than expected. The S&P 500 fell 1.4%, the Dow dropped 1.2% and the Nasdaq lost 2.4%.
Merck Earnings: Steady Results as Robust Keytruda Gains Help Mitigate Gardasil Pressure
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
RatingPrice TargetArgus Quick Note: Weekly Stock List for 07/29/2024: AI Spotlight on Healthcare
Artificial intelligence (AI) has become a pervasive technology in the Healthcare sector. Companies have been adopting AI in medical imaging, drug discovery, documentation, and administration. In medical imaging and diagnostics, AI is advancing rapidly in the detection of tumors, infections, and fractures. In drug discovery, vast data sets are being used to identify potential drugs to treat disease and predict their efficacy. AI also can improve trial design and create treatments for a wider range of people, including those with rare diseases. The technology also has helped to create more-efficient methods for documenting medical information with Automatic Speech Recognition (ASR). ASR enables voice-to-text technology and increases the productivity of medical staff by nearly 10%. For administrative tasks, AI has streamlined billing, scheduling, and fraud detection (a major issue that raises medical expenses for consumers). Here is a list of Argus BUY-rated Healthcare stocks that are leaders in the use of AI.